Key terms
About MESO
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MESO news
Mar 21
6:57am ET
Mesoblast Limited Announces New Share Issue
Mar 14
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Mar 13
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Mar 12
6:36am ET
Mesoblast (MESO) Gets a Hold from Piper Sandler
Mar 03
7:16am ET
Mesoblast Limited (MEOBF) Receives a Buy from Jefferies
Feb 29
7:48am ET
Mesoblast (MESO) Gets a Hold from Piper Sandler
Feb 14
7:50pm ET
FDA grants Mesoblast orphan-drug designation for Revascor
Feb 14
2:56pm ET
Mesoblast treatment of Hypoplastic Left Heart Syndrome gets orphan status
Jan 22
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Jan 18
6:39pm ET
Mesoblast receives RPD designation for Revascor from FDA
Jan 10
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Jan 09
7:50pm ET
Mesoblast trading halted, news pending
Jan 08
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Jan 07
7:36am ET
Jefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)
Jan 04
7:50pm ET
Mesoblast trading halted, news pending
Jan 03
7:39am ET
Jefferies Sticks to Its Buy Rating for Mesoblast Limited (MEOBF)
Dec 29
7:41am ET
Jefferies Sticks to Their Buy Rating for Mesoblast Limited (MEOBF)
Dec 26
7:38am ET
Jefferies Keeps Their Buy Rating on Mesoblast Limited (MEOBF)
No recent news articles are available for MESO
No recent press releases are available for MESO
MESO Financials
Key terms
Ad Feedback
MESO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MESO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range